S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil,
 irinotecan hydrochloride, and docetaxel, work in different ways to stop the growth of tumor
 cells, either by killing the cells or by stopping them from dividing. Combining more than one
 drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy
 is more effective in treating tumor cells.

 PURPOSE: This randomized phase II trial studies how well oxaliplatin, leucovorin calcium, and
 fluorouracil work compared to irinotecan hydrochloride and docetaxel in treating patients
 with esophageal cancer, gastric cancer, or gastroesophageal junction cancer.
OBJECTIVES:

 -  To assess progression-free survival of high-excision repair cross-complementing 1(ERCC1)
 patients with advanced or metastatic cancer of the esophagus, stomach, or
 gastroesophageal junction (GEJ) treated with FOLFOX comprising oxaliplatin, leucovorin
 calcium, and fluorouracil compared to those treated with irinotecan hydrochloride plus
 docetaxel.

 -  To assess progression-free survival of low-ERCC1 patients with advanced or metastatic
 cancer of the esophagus, stomach, or GEJ treated with FOLFOX compared to those treated
 with irinotecan hydrochloride plus docetaxel.

 -  To assess progression-free survival of low-ERCC1 patients with advanced or metastatic
 cancer of the esophagus, stomach, or GEJ treated with FOLFOX compared to high-ERCC1
 patients treated with FOLFOX.

 -  To assess overall survival of and toxicities in each of the two treatment arms in this
 group of patients.

 -  To assess the response probability (confirmed and unconfirmed, complete and partial
 responses) in the subset of patients with measurable disease in each of the two
 treatment arms.

 -  To explore whether there is evidence of interaction between treatment arm and ERCC1
 expression in this group of patients. (Exploratory)

 -  To bank tissue and blood for future translational medicine studies; a) To explore the
 relationship of ERCC-1 and ERCC-2 single nucleotide polymorphism (SNP) genotypes with
 clinical outcome in these patients; and b) To explore the association between germline
 variations in these SNPs and ERCC-1 mRNA expression in these patients. (Exploratory)

 OUTLINE: This is a multicenter study. Patients are stratified according to ERCC1 expression
 (high [≥ 1.7] vs low [< 1.7]), and disease site (esophageal vs gastric/gastroesophageal
 junction). Patients are randomized to 1 of 2 treatment arms.

 -  Arm I (FOLFOX): Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV
 over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1-2. Courses repeat
 every 14 days in the absence of disease progression or unacceptable toxicity.

 -  Arm II: Patients receive irinotecan hydrochloride IV over 90 minutes and docetaxel IV
 over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of
 disease progression or unacceptable toxicity.

 Blood and tumor tissue samples may be collected for ERCC1 expression analysis and future
 research studies.

 After completion of study treatment, patients are followed up every 3 months for up to 3
 years.
DISEASE CHARACTERISTICS:

 -  Patients must have unresectable advanced or metastatic histologically or cytologically
 confirmed adenocarcinoma of the esophagus, stomach, or gastroesophageal junction (GEJ)

 -  Patients must not have received treatment for metastatic or unresectable disease

 -  Patients must not have brain metastases

 -  Patients must have measurable and/or non-measurable disease

 -  Patients who have had HER-2 expression testing prior to patient consent to this study
 must be HER-2 negative; if HER-2 expression has not been tested prior to patient
 consent to this study, a second specimen must be submitted for HER-2 expression; if
 the specimen is HER-2 positive (or if HER-2 could not be evaluated), the patient will
 not be randomized

 -  Patients must have completed any prior neoadjuvant and adjuvant therapy for resectable
 disease at least 180 days prior to registration

 PATIENT CHARACTERISTICS:

 -  Zubrod performance status of 0-1

 -  Hemoglobin ≥ 9 g/dL

 -  Absolute neutrophil count (ANC) ≥ 1,500/mcL

 -  Platelets ≥ 100,000/mcL

 -  Total bilirubin ≤ 1.5 mg/dL regardless of whether patients have liver involvement
 secondary to tumor

 -  AST and ALT both ≤ 3 times institutional upper limit of normal (IULN) unless the liver
 is involved with tumor, in which case both AST and ALT must be ≤ 5 times IULN

 -  Serum creatinine < 1.5 mg/dL within 28 days prior to registration AND/OR calculated
 creatinine clearance > 60 mL/min

 -  Patients must not have motor or sensory neuropathy > Grade 1 using CTCAE version 4.0

 -  Patients must not be pregnant or nursing; women and men of reproductive potential must
 have agreed to use an effective contraceptive method

 -  No other prior malignancy is allowed except for the following: adequately treated
 basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
 stage I or II cancer from which the patient is currently in complete remission, or any
 other cancer from which the patient has been disease-free for five years

 PRIOR CONCURRENT THERAPY:

 -  See Disease Characteristics

 -  All palliative radiation therapy alone must be completed at least 14 days prior to
 registration

 -  Patient must have no plans to receive concurrent chemotherapy, hormonal therapy,
 radiotherapy, immunotherapy, or any other type of therapy for treatment of cancer
 while on this protocol treatment